For decades, the narrative around Parkinson’s disease treatment has focused primarily on dopamine replacement. The loss of ...

The FDA approved an expanded access program for troculeucel, making the treatment available to patients outside clinical trials.

Experts see tolebrutinib as part of a broader shift toward treatments that target the neurodegeneration in MS, not just its ...

Exploring how intermittent fasting influences gut-brain signaling, inflammation, and neuroprotection in neurodegenerative ...

Researchers discovered that people carrying the APOE ε4 gene variant share a unique immune-related protein signature across ...

FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, ...

GLP-1s - which mimic the effects of the hormone that stimulates insulin release, suppressing glucagon, and slowing gastric emptying - also have a range of other benefits.

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in people with the condition, finds the largest study of ...

Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in ...

UCSF researchers find that two FDA-approved cancer drugs significantly improve memory in Alzheimer’s mouse models and reduce ...